# Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

> **NCT02738866** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 60 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02738866
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-25
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738866, "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02738866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*